GREGORY GUBITZ

Mr. Gubitz is a co-founder and the Chief Executive Officer of HLS Therapeutics Inc. (TSX:HLS), a Canadian based, North American focused specialty pharmaceutical company.

Mr. Gubitz was Senior Vice President, Corporate Development and General Counsel of Biovail Corporation; formerly Canada’s largest publicly traded pharmaceutical company. In that capacity he was responsible for mergers & acquisitions and product acquisitions, culminating with the $7 billion merger of Biovail and Valeant Pharmaceutical International Inc. (TSX:VRX).  Prior to joining Biovail, for 10 years he was a senior executive with MDS Capital, a leading North American venture capital company, focused on healthcare. As Chief Operating Officer of MDS Capital, Mr. Gubitz was responsible for all operational aspects of the company with a total of $1 billion under management. Before joining MDS Capital, Mr. Gubitz was a partner at one of Canada’s leading international law firms, where he represented numerous public and private companies in a wide range of financings, mergers & acquisitions, joint ventures, and business transactions.

Mr. Gubitz attended McGill University where he received a Bachelor of Arts Degree in 1979 and a Bachelor of Laws Degree in 1982.  He was called to the Bar in the Province of Ontario in 1984.